- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02656498
[18F]THK-5351 Positron Emission Computed Tomography Study of Normal, Mild Cognitive Impairment, Alzheimer's Disease and Other Neurodegenerative Disease
December 11, 2020 updated by: Jae Seung Kim
An Open Label, Multicenter Study for Evaluation of the Clinical Utility of [18F]THK-5351 Positron Emission Computed Tomography in Cognitively Healthy Volunteers, Subjects With Mild Cognitive Impairment, Subjects With Alzheimer's Disease and Subjects With Other Neurodegenerative Diseases
This is a cross-sectional and longitudinal study to evaluate the clinical utility of [18F]THK-5351 positron emission computed tomography in cognitively healthy volunteers, mild cognitive impairment (MCI), Alzheimer's disease (AD) and other neurodegenerative patients.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
135
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Seoul, Korea, Republic of
- Samsung Medical Center
-
Seoul, Korea, Republic of, 05505
- Asan Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
General Subject Inclusion Criteria
In order to be eligible for participation in this trial, the subject must:
- Be ≥ 40 and < 80 years of age at the Screening Visit.
- Be able to read at a 6th grade level or equivalent, (as determined by the investigator, and must have a history of academic achievement and/or employment sufficient to exclude mental retardation.)
- Be able to speak, read, hear, and understand the language of the trial staff, and the informed consent form, and possess the ability to respond verbally to questions, follow instructions, and complete questionnaires and detailed neuropsychological test.
- Have results of clinical laboratory tests/physical examination, vital signs, and ECG within normal limits (at 90 days prior to [18F]THK-5351 positron emission computed tomography) or clinically acceptable to the investigator at screening.
- Be able to possess the ability to respond verbally to questions, follow instructions, and underwent research assessment, including brain images based on the investigator's judgment. Each subject is also able and willing to adhere visit schedules.
- If female, not be of childbearing potential as indicated by one of the following
- Each subject (or legal representative) must sign the informed consent form in accordance with local requirements after the scope and nature of the investigation have been explained to them, and before screening assessments.
- Each subject must be willing to provided blood samples for genotyping apolipoprotein E
- Cognitively Healthy Subjects
- MCI Subjects
- AD Subjects
- Subjects with other neurodegenerative disease
Exclusion Criteria
The subject must be excluded from participating in the trial if the subject fulfil any single criteria described below:
1. General Exclusion Criteria
- Based on the investigators' judgement, if the patient is not capable of communicating with the site personnel, if the patient is not proficient in the language in which the psychometric tests will be completed, or if the patient is not sufficient for compliance with the study procedures.
- The patient has an abnormal physical examination or abnormal laboratory test results at the screening that are clinically significant to affect results of the research, as judged by the investigator.
- If the patient has or is suspicious of having a hypersensitivity or allergy to [18F] THK-5351 or its derivatives.
- The patient is pregnant, is attempting to become pregnant, or is nursing (breast-feeding) children.
- The patient has a history of alcoholism or drug dependency/abuse within the last 2 years before screening.
- The patient has contraindications to undergo positron emission computed tomography or MRI, which include but are not restricted to the examples below: claustrophobia, cardiac pacemaker, metal devices around the eye or spinal cord, cochlear implant, etc.) at the screening visit.
- The patient has been treated with any investigational medicinal product (IMP) within 30 days prior to the screening visit.
- The patient has been tested positive for hepatitis B surface antigen (HBsAg), hepatitis C virus antibodies (anti-HCV), HIV Antibody, or syphilis serum test at the screening visit.
- The patient has been receiving an anti-cholinergic drug in a regular basis within 3 months prior to the screening visit.
- The patient has evidence of a clinically relevant neurological disorders other than the disease being studied (i.e., prodromal AD) at screening, including but not limited to: territorial cerebral infarction, intracranial hemorrhage, multiple sclerosis, neurosyphilis, mental retardation, hypoxic encephalopathy, major head trauma with loss of consciousness that led to persistent cognitive deficits.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cognitively Healthy Subjects
Cognitively healthy subjects will receive an IV injection, [18F]THK-5351 at baseline and also receive an IV injection, [18F]THK-5351 at 24 months.
|
Imaging for evaluating the accumulation of abnormal tau protein in the brain
Other Names:
|
Experimental: MCI Subjects
MCI Subjects will receive an IV injection, [18F]THK-5351 at baseline and also receive an IV injection, [18F]THK-5351 at 24 months.
|
Imaging for evaluating the accumulation of abnormal tau protein in the brain
Other Names:
|
Experimental: AD Subjects
AD Subjects will receive an IV injection, [18F]THK-5351 at baseline and also receive an IV injection, [18F]THK-5351 at 24 months.
|
Imaging for evaluating the accumulation of abnormal tau protein in the brain
Other Names:
|
Experimental: Subjects with other neurodegenerative disease
Subjects with other neurodegenerative disease will receive an IV injection, [18F]THK-5351 at baseline.
|
Imaging for evaluating the accumulation of abnormal tau protein in the brain
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cross-sectional [18F]THK-5351 Imaging Results
Time Frame: 50-70 minutes post injection
|
Compare Standard uptake value ratio (SUVR) and distribution of [18F]THK-5351 in subjects with MCI, subjects with AD, subjects with other neurodegenerative disease and cognitively healthy individuals.
|
50-70 minutes post injection
|
Assess the rate of change of tau deposition as measured by [18F]THK-5351 uptake (SUVR) over time
Time Frame: 24 months
|
Compare Standard uptake value ratio (SUVR) and distribution of [18F]THK-5351 in subjects with MCI, subjects with AD, subjects with other neurodegenerative disease and cognitively healthy individuals.
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Correlation between standard uptake value ratio (SUVR) of [18F]THK-5351 positron emission computed tomography and neuropsychiatric test scores
Time Frame: 50-70 minutes post-injection
|
We will evaluate correlation between standard uptake value ratio (SUVR) [18F]THK-5351 positron emission computed tomography and scores of neuropsychiatric test
|
50-70 minutes post-injection
|
Correlation between standard uptake value ratio (SUVR) of [18F]THK-5351 positron emission computed tomography and indices of structural MRI
Time Frame: 50-70 minutes post-injection
|
We will evaluate correlation between standard uptake value ratio (SUVR) [18F]THK-5351 positron emission computed tomography and indices of structural MRI including cortical thickness, hippocampal atrophy.
|
50-70 minutes post-injection
|
Correlation between standard uptake value ratio (SUVR) of [18F]THK-5351 positron emission computed tomography and indices of functional MRI
Time Frame: 50-70 minutes post-injection
|
We will evaluate correlation between standard uptake value ratio (SUVR) [18F]THK-5351 positron emission computed tomography and indices of functional MRI derived from diffusion tensor imaging and resting state functional MRI.
|
50-70 minutes post-injection
|
Correlation between standard uptake value ratios (SUVR) and distribution of [18F]THK-5351 positron emission computed tomography and amyloid positron emission computed tomography
Time Frame: 50-70 minutes post-injection
|
We will evaluate correlation between standard uptake value ratio (SUVR) and distribution of [18F]THK-5351 positron emission computed tomography and those of amyloid positron emission computed tomography
|
50-70 minutes post-injection
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Jae Seung Kim, M.D.,Ph.D., Asan Medical Center
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Chun MY, Lee J, Jeong JH, Roh JH, Oh SJ, Oh M, Oh JS, Kim JS, Moon SH, Woo SY, Kim YJ, Choe YS, Kim HJ, Na DL, Jang H, Seo SW. 18F-THK5351 PET Positivity and Longitudinal Changes in Cognitive Function in beta-Amyloid-Negative Amnestic Mild Cognitive Impairment. Yonsei Med J. 2022 Mar;63(3):259-264. doi: 10.3349/ymj.2022.63.3.259.
- Park JE, Yun J, Kim SJ, Shim WH, Oh JS, Oh M, Roh JH, Seo SW, Oh SJ, Kim JS. Intra-individual correlations between quantitative THK-5351 PET and MRI-derived cortical volume in Alzheimer's disease differ according to disease severity and amyloid positivity. PLoS One. 2019 Dec 13;14(12):e0226265. doi: 10.1371/journal.pone.0226265. eCollection 2019.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 11, 2016
Primary Completion (Actual)
December 31, 2019
Study Completion (Actual)
December 31, 2019
Study Registration Dates
First Submitted
January 12, 2016
First Submitted That Met QC Criteria
January 13, 2016
First Posted (Estimate)
January 15, 2016
Study Record Updates
Last Update Posted (Actual)
December 14, 2020
Last Update Submitted That Met QC Criteria
December 11, 2020
Last Verified
December 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- THK-15002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neurodegenerative Diseases
-
Fujian Medical University Union HospitalRecruitingNeurodegenerative DisordersChina
-
Imperial College LondonWithdrawn
-
University Hospital, Strasbourg, FranceRecruitingNeurodegenerative DisordersFrance
-
First Affiliated Hospital of Fujian Medical UniversityRecruitingNeurodegenerative DisordersChina
-
University of PennsylvaniaAvid RadiopharmaceuticalsRecruiting
-
Fujian Medical University Union HospitalRecruitingNeurodegenerative DisorderChina
-
ACADIA Pharmaceuticals Inc.CompletedNeuropsychiatric Symptoms Related to Neurodegenerative DiseaseUnited States, Russian Federation, Serbia, Poland, Georgia, Czechia, Bulgaria, Colombia, Mexico, Romania, South Africa, Ukraine
-
ACADIA Pharmaceuticals Inc.CompletedNeuropsychiatric Symptoms Related to Neurodegenerative DiseaseSerbia, United States, Poland, Georgia, Russian Federation, Bulgaria, Colombia, Czechia, Mexico, Romania, South Africa, Ukraine
-
National Institute of Neurological Disorders and...Completed
-
Mei HanNot yet recruiting
Clinical Trials on [18F]THK-5351
-
Columbia UniversityNational Institute on Aging (NIA)WithdrawnDiabetes Mellitus | Alzheimer DementiaUnited States
-
Chang Gung Memorial HospitalRecruitingPost-stroke Dementia, Vascular Mild Cognitive ImpairmentTaiwan
-
Asan FoundationCompletedAlzheimer DiseaseKorea, Republic of
-
William Charles KreislNational Institute on Aging (NIA)Terminated
-
Chang Gung Memorial HospitalCompleted
-
Chang Gung Memorial HospitalCompletedPost-stroke Dementia | Vascular Mild Cognitive ImpairmentTaiwan
-
Chang Gung Memorial HospitalCompletedMajor Depressive DisorderTaiwan
-
Chang Gung Memorial HospitalCompleted
-
Adam BrickmanNational Institute on Aging (NIA)Completed
-
Genentech, Inc.Completed